Business Wire

CWAN Reports 800+ AI Agents Now Available for Deployment Across $10 Trillion in Client Assets

5.11.2025 23:15:00 EET | Business Wire | Press release

Share

Clearwater Analytics (NYSE: CWAN), the most comprehensive technology platform for investment management, today announced the global deployment of CWAN GenAI, a newly-launched, embedded generative AI platform that can be deployed to transform investment management, risk management, reporting and operations across more than $10 trillion in institutional assets.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105092732/en/

What sets CWAN GenAI apart from the experimental AI tools flooding the market is its production-ready integration. Unlike copilots or chat tools layered onto legacy systems, CWAN GenAI is fully integrated and deployed into production on CWAN’s front-to-back platform, enabling clients to work alongside AI as collaborative partners in their investment operations. The platform currently supports 800+ AI agents created by CWAN clients and internal teams, plus 20 highly trained domain-specific agents. These agents work in tandem with investment professionals, automating data-intensive tasks and augmenting human expertise across reconciliation, reporting, portfolio analysis, and client communications.

“We're witnessing the largest operational transformation in investment management since electronic trading,” said Sandeep Sahai, CEO at CWAN. “While the industry debates AI’s potential, our clients are already operating with autonomous intelligence that processes more data in a day than traditional systems handle in months. This is about fundamentally reimagining how institutional investment operations function in real-time.”

“The industry has been waiting for AI that can handle the complexity and scale of institutional operations,” said Souvik Das, Chief Technology Officer at CWAN. “We’ve engineered AI agents that can autonomously execute millions of tasks daily while maintaining the precision and auditability that institutions require. Our platform transforms operational efficiency, accelerates decision-making, and gives institutions confidence in leveraging AI across investment portfolios at enterprise scale.”

“CWAN’s agentic workflow architecture, built on AWS, demonstrates how modern investment platforms can scale while maintaining institutional-grade security and compliance standards,” said Brian Cassin, Capital Markets Leader at AWS. “By enabling real-time data processing, low-latency model orchestration, and encrypted model execution at institutional scale, CWAN can compress their data cycles (from 30 days to 24 hours), allowing their expanded customer base to identify issues and make decisions with speed and confidence.”

AI That’s Already Changing the Industry

The proof lies in the performance metrics emerging from CWAN’s client base, where CWAN GenAI is delivering measurable performance improvements:

  • 90% reduction in manual reconciliation effort
  • 80% faster regulatory and accounting report generation
  • 50% faster financial close cycles

How Financial Professionals are Using CWAN GenAI

  • Asset Managers use CWAN GenAI to automate variance analysis, fee calculations, and performance attribution, closing books faster and delivering error-free, audit-ready reports to regulators and clients the same day issues arise, strengthening trust and reducing restatement risk.
  • Risk Analysts rely on CWAN GenAI to continuously scan concentration and counterparty risk across portfolios, running daily stress tests across asset classes and flagging emerging threats early so CIOs and risk committees can act before market shocks hit balance sheets.
  • Operations Teams deploy CWAN GenAI for autonomous trade settlement, real-time cash management, and exception handling that resolves 90% of operational issues without human intervention.

Operational Intelligence at Work

CWAN GenAI operates as a 24/7 embedded operations layer within its unified platform—spanning accounting, trading, compliance, performance, and reporting—where its AI agents are ready to act with precision and transparency. When deployed by clients, the CWAN platform can:

  • Reconcile portfolios autonomously, analyzing billions of data points daily.
  • Generate audit-ready reports on demand via natural-language queries.
  • Answer complex portfolio questions instantly using live accounting and trading data.
  • Schedule workflow automations that continuously improve through feedback and learning.

The technology foundation enabling these results reflects a strategic partnership with cloud infrastructure leaders like AWS, whose robust platform powers CWAN GenAI with real-time data processing, low-latency model orchestration, and encrypted model execution, ensuring both performance and compliance at scale.

“CWAN GenAI’s combination of speed, accuracy, scalability and security—underpinned by AWS’s computational power and governance frameworks—empowers global financial institutions to deliver competitive advantage while meeting the rigorous regulatory requirements their clients demand,” added Cassin, AWS Capital Markets Leader.

CWAN’s comprehensive approach solves growing industry challenges for institutional investors who are under pressure from surging data volumes, tighter regulation, and relentless operational strain. While most competitors are still testing out pilots, CWAN is already executing at global scale, freeing thousands of hours weekly, transforming business models and enabling firms to shift from reactive operations to real-time intelligence so they can respond instantly to market moves, regulatory challenges and client needs.

About CWAN

Clearwater Analytics (NYSE: CWAN) is transforming investment management with the industry’s most comprehensive cloud-native platform for institutional investors across global public and private markets. While legacy systems create risk, inefficiency, and data fragmentation, CWAN’s single-instance, multi-tenant architecture delivers real-time data and AI-driven insights throughout the investment lifecycle. The platform eliminates information silos by integrating portfolio management, trading, investment accounting, reconciliation, regulatory reporting, performance, compliance, and risk analytics in one unified system. Serving leading insurers, asset managers, hedge funds, banks, corporations, and governments, CWAN supports over $10 trillion in assets globally.Learn more at www.cwan.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251105092732/en/

Contacts

Media Contact:
Claudia Cahill, Head of Communications and PR | +1 208-433-1200 | press@cwan.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye